TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9043028
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin 3 (rhIL‐3) 10 microg kg(‐1) day(‐1) (days 5‐9) + G‐CSF 5.0 microg kg(‐1) day(‐1) (days 7‐16)
Study: 9043028
Drug: Paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135 mg m(‐2) day 1), ifosfamide (1.2 g m(‐2) day(‐1) days 2-4), cisplatin (30 mg m(‐2) day(‐1) days 2-4) + G‐CSF 5.0 microg kg(‐1) day(‐1) (days 7-16)
Study: 7639381
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of 2% lidocaine IV as a bolus (Group B)
Study: 7639381
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg of 2% lidocaine IV for 5 min (Group C)
Study: 7639381
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of 2% lidocaine IV for 5 min (Group D)
Study: 7639381
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of 1.5% lidocaine epidurally as a bolus (Group E)
Study: 3235818
Drug: Alpidem (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem (50 mg)
Study: 3235818
Drug: Alpidem (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem (25 mg)
Study: 3235818
Drug: Alcohol +
Normalized name: Benzyl alcohol + eucalyptus oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol + Alpidem (50 mg)
Study: 3235818
Drug: Alcohol +
Normalized name: Benzyl alcohol + eucalyptus oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol + Alpidem (25 mg)
Study: 26659384
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl injection
Study: 25149384
Drug: Yinxieling decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinxieling decoction (8 weeks treatment)
Study: 23129602
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 350 mg
Study: 23129602
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 420 mg
Study: 16022920
Drug: Topotecan 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.25 mg/(m² day) IV days 1-5, cisplatin 50 mg/m² IV day 5 (T/C)
Study: 16022920
Drug: Topotecan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 0.75 mg/(m² day) IV days 1-5, etoposide 60 mg/(m² day) IV days 1-5 (T/E)
Study: 12675729
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of elemental Fe per day
Study: 11199506
Drug: PDE III
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDE III inhibitor (amrinone, 1 mg/kg)
Study: 11199506
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PDE III inhibitor)
Study: 1728484
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amrinone
Study: 1728484
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amrinone (after digoxin infusion)
Study: 6374931
Drug: Sotalol hydrochloride
Normalized name: Sotalol Hydrochloride
DrugBank: Sotalol (DB00489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sotalol hydrochloride 160 mg/d plus hydrochlorothiazide 25 mg/d
Study: 6374931
Drug: Reserpine 0.1
Normalized name: reserpine 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserpine 0.1 mg/d plus hydrochlorothiazide 25 mg/d
Study: 22995464
Drug: Royal Jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal Jelly (RJ) 3000 mg in 100 ml liquid/day for 6 months
Study: 8544420
Drug: symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: symptomatic therapy
Study: 25511347
Drug: Paracetamol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol group
Study: 25511347
Drug: Preemptive paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive paracetamol group
Study: 21817105
Drug: Intravenous lipids
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipids
Study: 21817105
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intravenous lipids)
Study: 12736088
Drug: D-cycloserine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (daily oral dose of 50 mg)
Study: 10912746
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg trandolapril once daily for 6 weeks
Study: 10912746
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg losartan once daily for 6 weeks
Study: 9378688
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg q.d. at 10:00 p.m. for 12 weeks
Study: 7691784
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy with concomitant mitomycin C
Study: 7691784
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy alone
Study: 3757322
Drug: Acetate metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate metabolism
Study: 27889723
Drug: 100,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 IU of oral cholecalciferol (vitamin D)
Study: 25132872
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (two doses of 15 mg/kg preoperative and postoperative)
Study: 20721517
Drug: Concomitant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of beta-blockers and dobutamine (Group C, n=11)
Study: 20721517
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of beta-blockers to start dobutamine (Group B, n=25)
Study: 20721517
Drug: No beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blockers used (Group A, n=8)
Study: 18603572
Drug: Long-acting octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting octreotide (30 mg)
Study: 11874177
Drug: GH alone
Normalized name: LINER,SECURELY YOURS,PAPER PAK #GH-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH alone (Saizen, Ares‐Serono, Geneva) 18 IU/m2/week (0.2 mg/kg/week)
Study: 11874177
Drug: GH +
Normalized name: Delsym Cough + Cold Daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH + Ox 0.1 mg/kg/day p.o.
Study: 7556325
Drug: Heparin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin at 0.1, 0.25, 0.5 and 1 IU/ml added to TPN infusions
Study: 2272193
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg flupenthixol dihydrochloride
Study: 2272193
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg dothiepin hydrochloride
Study: 7374100
Drug: Intraduodenal L-phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal L-phenylalanine (100 mM)
Study: 7374100
Drug: Intraduodenal L-phenylalanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal L-phenylalanine
Study: 7374100
Drug: L-phenylalanine absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-phenylalanine absorption rates
Study: 21232979
Drug: Gabapentin (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1.2 g/d orally before and for 2 days after surgery)
Study: 20054753
Drug: Rivastigmine, initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine, initial dose of 3 mg/day b.i.d., escalated to maximum tolerated dose in at least 4-week intervals.
Study: 17926612
Drug: Combined acupuncture
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined acupuncture and medicine group (acupuncture balance points 'Jiangya' and 'Shenbing' with small dose of hypotensor, Irbesartan)
Study: 17926612
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (oral administration of Irbesartan and Fosinopril)
Study: 17926612
Drug: Combined acupuncture
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined acupuncture and medicine group
Study: 15178812
Drug: Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin) added to standard carboplatin/paclitaxel chemotherapy
Study: 15178812
Drug: Standard carboplatin/paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard carboplatin/paclitaxel chemotherapy alone
Study: 15178812
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with chemotherapy in patients with nonsquamous histologies
Study: 2833178
Drug: CE therapy
Normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CE therapy (CDDP plus etoposide)
Study: 2833178
Drug: CE-AVN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE-AVN therapy (ACNU, VCR plus procarbazine)
Study: 26658268
Drug: TIVA +
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA + ramosetron (0.3 mg ramosetron just before anaesthesia induction, remifentanil and propofol anaesthesia)
Study: 22507665
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of lithium
Study: 15787886
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg/day
Study: 15787886
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (high doses)
Study: 12456032
Drug: Sorbent dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbent dialysis and standardized conventional medical treatment
Study: 12456032
Drug: Ongoing medical
Normalized name: Ongo-Fin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing medical treatment alone
Study: 10625865
Drug: Waiting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting treatment group (control)
Study: 2207304
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lomefloxacin
Study: 2207304
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg lomefloxacin
Study: 1316059
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg lomefloxacin
Study: 2207304
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lomefloxacin
Study: 2207304
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg lomefloxacin
Study: 7445655
Drug: D 600
Normalized name: Guaiphen-D 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: D 600 (0.03 mg/kg i.v.)
Study: 7445655
Drug: Ro 11-1781
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 11-1781 (1.0 mg/kg i.v.)
Study: 30666700
Drug: VAS203 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAS203 (10 mg/kg body weight)
Study: 28142347
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) - 3 sessions
Study: 28142347
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection - 80 mg methylprednisolone, 1 injection
Study: 21392096
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg daily) plus Simvastatin (40 mg daily)
Study: 19713268
Drug: Daily movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily movement training
Study: 19713268
Drug: Daily social
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily social training
Study: 17539268
Drug: Regimen-A: 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-A: 300 mg DHA followed by 750 mg MQ and 300 mg DHA 6 and 24 hours later
Study: 17539268
Drug: Regimen-B: 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-B: 300 mg DHA followed by 300 mg DHA and 750 mg MQ at 24 hours
Study: 15126524
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitor (LAF237); 100 mg daily, n = 18
Study: 11274902
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus sulodexide (IS)
Study: 7521713
Drug: Choline magnesium
Normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline magnesium trisalicylate (CMT) 1500 mg
Study: 2683326
Drug: Cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (400 mg tablet once daily)
Study: 2683326
Drug: Trimethoprim (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim (160 mg)/sulfamethoxazole (800 mg, one tablet every 12 hours)
Study: 821573
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy during surgical treatment
Study: 821573
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic therapy during surgical treatment
Study: 30345864
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil citrate 20 mg orally three times a day, in addition to fish oil and zinc supplementation
Study: 30345864
Drug: placebo (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (tablets similar to sildenafil)
Study: 18183403
Drug: 1,350 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,350 ml of low-density barium (VoLumen)
Study: 18183403
Drug: 900 ml
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 ml of low-density barium (VoLumen) and 450 ml of water
Study: 9088654
Drug: Oral cow
Normalized name: Cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cow milk challenge (DBPCFC)
Study: 1545355
Drug: 155-mg oral
Normalized name: formic acid 155 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 155-mg oral tablet of hydroxychloroquine
Study: 1545355
Drug: 155-mg iv
Normalized name: formic acid 155 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 155-mg iv infusion of racemic hydroxychloroquine
Study: 1395837
Drug: NIAID vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIAID vaccine
Study: 3903646
Drug: BIVS vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIVS vaccine
Study: 3903646
Drug: Vaccine +
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine + hepatitis B immune globulin
Study: 20717750
Drug: Goal hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal hemoglobin (HGB) concentration of at least 11.5 g/dl
Study: 20717750
Drug: Goal hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal hemoglobin (HGB) concentration of at least 10 g/dl
Study: 16086946
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of travoprost 0.004%/timolol 0.5% once daily
Study: 16086946
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of travoprost 0.004%/timolol 0.5%
Study: 12451188
Drug: IFNbeta‐1a 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 44 micro g subcutaneously three times weekly (tiw)
Study: 12451188
Drug: IFNbeta‐1a 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 30 micro g IM once weekly (qw)
Study: 12451188
Drug: IFNbeta‐1a 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 44 micro g tiw
Study: 12451188
Drug: IFNbeta‐1a 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 30 micro g qw
Study: 11044464
Drug: LNG-IUS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-IUS treatment for 6 months
Study: 11044464
Drug: LNG-IUS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-IUS treatment for 12 months
Study: 1332987
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no implant)
Study: 4015741
Drug: Suprofen 200
Normalized name: suprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprofen 200 mg/ml intravenous injection or infusion
Study: 24423366
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 70 μg (2800 IU) cholecalciferol for 52 weeks
Study: 18414870
Drug: Neutral oral
Normalized name: Nupro Neutral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral oral contrast agent (3% mannitol)
Study: 18414870
Drug: Positive oral
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive oral contrast medium
Study: 8880676
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture (5 or more treatments)
Study: 8880676
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (4 or fewer treatments or refused)
Study: 27151071
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality cognitive therapy
Study: 23301470
Drug: Loratadine tablets
Normalized name: Loratadine Tablets
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine tablets (western medication)
Study: 17697063
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (once-daily)
Study: 16274417
Drug: Flecainide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (1.5 mg/kg per day)
Study: 16274417
Drug: Flecainide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (3.0 mg/kg per day)
Study: 10219654
Drug: Chlorpheniramine and
Normalized name: Chlorpheniramine and epinephrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine and famotidine (H1- and H2-receptor antagonist)
Study: 10219654
Drug: Hydroxyzine (H1-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (H1-receptor antagonist)
Study: 7529522
Drug: MIP (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIP (mitomycin 6 mg m‐2, ifosfamide 3 g m‐2, cisplatinum 80 mg m‐2 on day 1 every 28 days)
Study: 7529522
Drug: PC (cisplatinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC (cisplatinum 60 mg m‐2 and carboplatin 400 mg m‐2 on day 1 every 28 days)
Study: 2212185
Drug: short-term dynamically
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: short-term dynamically oriented individual therapy
Study: 727423
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate (10 ml 10%)
Study: 727423
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (10 ml 5.5%)
Study: 23975134
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood combined with hydroxychloroquine sulfate tablets
Study: 26525549
Drug: Hydroxychloroquine sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine sulfate tablets alone
Study: 24225205
Drug: Home medication
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home medication review (HMR) and medication management (MM) conducted by Dementia Care Manager (DCM) in cooperation with pharmacists and general practitioners.
Study: 19575742
Drug: Modified patient-maintained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified patient-maintained target-controlled infusion (TCI) of propofol
Study: 19575742
Drug: Patient-controlled Entonox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled Entonox inhalation
Study: 16765849
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music with movement intervention (twice a week for 4 weeks)
Study: 15301650
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) in group therapy format
Study: 15301650
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) in individual face-to-face therapy
Study: 15301650
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) through brief individual telephone consultations
Study: 11142580
Drug: 0.2% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% glyceryl trinitrate ointment (PMF 303)
Study: 11142580
Drug: Common preparation
Normalized name: common toad cutaneous gland preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common preparation of glyceryl trinitrate ointment
Study: 2809258
Drug: Conventional pertussis
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pertussis vaccine
Study: 27296723
Drug: Play &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Play & Grow intervention (weekly one-hour activity sessions for 10 weeks)
Study: 18324427
Drug: Caspofungin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin therapy for invasive candidiasis (IC)
Study: 18324427
Drug: Caspofungin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin therapy for invasive aspergillosis (IA)